Advemto is a company headquartered in New Zealand. Brouky records 1 investor associated with the company.
Advemto develops technology to map complex cell functions to genetic sequences at a large scale, aiming to eliminate bottlenecks in preclinical validation for next-generation therapeutics and TechBio without requiring new instruments.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.